Kalaiarasan Ponnusamy

Prof. Kalaiarasan Ponnusamy

orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 September 2021 in Nature
Verified
Journal Article
Open access
PDF file
PMPetra Mlcochova
Petra Mlcochova
SKSteven A. Kemp
Steven A. Kemp
MDMahesh Shanker Dhar
Mahesh Shanker Dhar
GPGuido Papa
Guido Papa
BMBo Meng
Bo Meng
RGRavindra Gupta
Ravindra Gupta
The B.1.617.2 (Delta) variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first identified in the state of Maharashtra in late 2020 and spread throughout India, outcompeting pre-existing lineages including B.1.617.1 (Kappa) and B.1.1.7 (Alpha)1. In vitro, B.1.617.2 is sixfold less sensitive to serum neutralizing antibodies from recovered individuals, and eightfold less sensitive to vaccine-elicited antibodies, compared with wild-type Wuhan-1 bearing D614G. Serum neutralizing titres against B.1.617.2 were lower in ChAdOx1 vaccinees than in BNT162b2 vaccinees. B.1.617.2 spike pseudotyped viruses exhibited compromised sensitivity to monoclonal antibodies to the receptor-binding domain and the amino-terminal domain. B.1.617.2 demonstrated higher replication efficiency than B.1.1.7 in both airway organoid and human airway epithelial systems, associated with B.1.617.2 spike being in a predominantly cleaved state compared with B.1.1.7 spike. The B.1.617.2 spike protein was able to mediate highly efficient syncytium formation that was less sensitive to inhibition by neutralizing antibody, compared with that of wild-type spike. We also observed that B.1.617.2 had higher replication and spike-mediated entry than B.1.617.1, potentially explaining the B.1.617.2 dominance. In an analysis of more than 130 SARS-CoV-2-infected health care workers across three centres in India during a period of mixed lineage circulation, we observed reduced ChAdOx1 vaccine effectiveness against B.1.617.2 relative to non-B.1.617.2, with the caveat of possible residual confounding. Compromised vaccine efficacy against the highly fit and immune-evasive B.1.617.2 Delta variant warrants continued infection control measures in the post-vaccination era.

19 November 2021 in Science
Verified
Journal Article
Open access
MDMahesh S. Dhar
Mahesh S. Dhar
RMRobin Marwal
Robin Marwal
RVRadhakrishnan Vs
Radhakrishnan Vs
KPKalaiarasan Ponnusamy
Kalaiarasan Ponnusamy
BJBani Jolly
Bani Jolly
SCSarah S. Cherian
Sarah S. Cherian
Deadly surge in Delhi: In the spring of 2021, Delhi, India experienced a wave of coronavirus cases that overwhelmed healthcare services despite the population showing a high level of immune positivity. Dhar et al . collated a mixture of serosurveillance, quantitative polymerase chain reaction, and genomic data, finding that waves of variants had passed through the Delhi population during 2020 and 2021. The alpha (B.1.1.7) variant dominated in March 2021 and was rapidly replaced by the delta (B.1.617.2) variant in April and May 2021. The delta variant outcompeted its predecessors by mutations that enhanced replication, immune evasion, and host receptor avidity, thus increasing transmissibility, reinfection, and vaccination breakthrough. —CA

1 September 2015 in International Journal of Biological Macromolecules
Verified
Journal Article
Closed access
SCSumit Kumar Chaturvedi
Sumit Kumar Chaturvedi
PAParvez Alam
Parvez Alam
JKJaved Masood Khan
Javed Masood Khan
MSMohd. Khursheed Siddiqui
Mohd. Khursheed Siddiqui
KPKalaiarasan Ponnusamy
Kalaiarasan Ponnusamy
RKRizwan Khan
Rizwan Khan

9 May 2021 in bioRxiv
Verified
Preprint
Open access
PDF file
IFIsabella Ferreira
Isabella Ferreira
RDRawlings Datir
Rawlings Datir
GPGuido Papa
Guido Papa
SKSteven Kemp
Steven Kemp
BMBo Meng
Bo Meng
RGRavindra Gupta
Ravindra Gupta
The SARS-CoV-2 B.1.617.2 (Delta) variant was first identified in the state of Maharashtra in late 2020 and spread throughout India, outcompeting pre-existing lineages including B.1.617.1 (Kappa) and B.1.1.7 (Alpha). In vitro , B.1.617.2 is 6-fold less sensitive to serum neutralising antibodies from recovered individuals, and 8-fold less sensitive to vaccine-elicited antibodies as compared to wild type Wuhan-1 bearing D614G. Serum neutralising titres against B.1.617.2 were lower in ChAdOx-1 versus BNT162b2 vaccinees. B.1.617.2 spike pseudotyped viruses exhibited compromised sensitivity to monoclonal antibodies against the receptor binding domain (RBD) and N-terminal domain (NTD), in particular to the clinically approved bamlavinimab and imdevimab monoclonal antibodies. B.1.617.2 demonstrated higher replication efficiency in both airway organoid and human airway epithelial systems as compared to B.1.1.7, associated with B.1.617.2 spike being in a predominantly cleaved state compared to B.1.1.7. Additionally we observed that B.1.617.2 had higher replication and spike mediated entry as compared to B.1.617.1, potentially explaining B.1.617.2 dominance. In an analysis of over 130 SARS-CoV-2 infected healthcare workers across three centres in India during a period of mixed lineage circulation, we observed substantially reduced ChAdOx-1 vaccine efficacy against B.1.617.2 relative to non-B.1.617.2. Compromised vaccine efficacy against the highly fit and immune evasive B.1.617.2 Delta variant warrants continued infection control measures in the post-vaccination era.

4 April 2011 in Breast Cancer Research
Verified
Journal Article
Open access
PDF file
NSNiloo Srivastava
Niloo Srivastava
SMSiddharth Manvati
Siddharth Manvati
ASArchita Srivastava
Archita Srivastava
RPRanjana Pal
Ranjana Pal
KPKalaiarasan Ponnusamy
Kalaiarasan Ponnusamy
RBRameshwar Nk Bamezai
Rameshwar Nk Bamezai
New levels of gene regulation with microRNA (miR) and gene copy number alterations (CNAs) have been identified as playing a role in various cancers. We have previously reported that sporadic breast cancer tissues exhibit significant alteration in H2AX gene copy number. However, how CNA affects gene expression and what is the role of miR, miR-24-2, known to regulate H2AX expression, in the background of the change in copy number, are not known. Further, many miRs, including miR-24-2, are implicated as playing a role in cell proliferation and apoptosis, but their specific target genes and the pathways contributing to them remain unexplored.

15 April 2019 in Molecular Plant Pathology
Verified
Journal Article
Open access
PDF file
Prabu GnanasekaranPrabu Gnanasekaran
Prabu Gnanasekaran
KPKalaiarasan Ponnusamy
Kalaiarasan Ponnusamy
SCSupriya Chakraborty
Supriya Chakraborty
Summary: Geminivirus disease complexes potentially interfere with plants physiology and cause disastrous effects on a wide range of economically important crops throughout the world. Diverse geminivirus betasatellite associations exacerbate the epidemic threat for global food security. Our previous study showed that βC1, the pathogenicity determinant of geminivirus betasatellites induce symptom development by disrupting the ultrastructure and function of chloroplasts. Here we explored the betasatellite‐virus‐chloroplast interaction in the scope of viral pathogenesis as well as plant defence responses, using Nicotiana benthamiana —Radish leaf curl betasatellite (RaLCB) as the model system. We have shown an interaction between RaLCB‐encoded βC1 and one of the extrinsic subunit proteins of oxygen‐evolving complex of photosystem II both in vitro and in vivo . Further, we demonstrate a novel function of the Nicotiana benthamiana oxygen‐evolving enhancer protein 2 (PsbP), in that it binds DNA, including geminivirus DNA. Transient silencing of PsbP in N. benthamiana plants enhances pathogenicity and viral DNA accumulation. Overexpression of PsbP impedes disease development during the early phase of infection, suggesting that PsbP is involved in generation of defence response during geminivirus infection. In addition, βC1‐PsbP interaction hampers non‐specific binding of PsbP to the geminivirus DNA. Our findings suggest that betasatellite‐encoded βC1 protein accomplishes counter‐defence by physical interaction with PsbP reducing the ability of PsbP to bind geminivirus DNA to establish infection.